Reducing the risk of age-related macular degeneration progression - five-year follow-up study in Ukraine and Moldova

Nov 5, 2025Romanian journal of ophthalmology

Lowering the risk of age-related vision loss over five years in Ukraine and Moldova

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

In a study involving 163 patients with early and intermediate age-related macular degeneration (AMD), adherence to a specific nutraceutical formula was associated with a 3.24-fold reduction in disease progression risk over five years.

The five-year prevalence of early and intermediate AMD was recorded at 7.1% in Odesa, 6.6% in Kharkiv, and 6.3% in Moldova.
Patients who consistently took the AREDS2 nutraceutical formula experienced a significant reduction in the risk of AMD progression compared to those who took various vitamin-antioxidant complexes irregularly.
Photobiomodulation (PBM) treatments every six months were provided to all participants.
It is recommended that patients with early and intermediate AMD regularly use the AREDS2 nutraceutical formula and undergo PBM treatments to potentially improve outcomes.

AI simplified

This open prospective study aimed to evaluate the dynamics of progression of early and intermediate age-related macular degeneration (AMD) against the background of continuous use of the nutraceutical formula AREDS2, which includes omega-3 polyunsaturated fatty acids (PUFAs), vitamin D, resveratrol, and photobiomodulation (PBM), over a 5-year follow-up in patients from Ukraine and Moldova. Examining 126,400 patients, 163 patients (304 eyes) with early and intermediate stages of AMD were treated (5-year follow-up). Patients were divided into two groups. Patients in the 1st group (149 eyes) were prescribed a nutraceutical formula based on AREDS2 with omega-3 PUFAs, vitamin D, and resveratrol (Nutrof®Forte 1 capsule once a day continuously). The second group (155 eyes) included patients who irregularly took various vitamin-antioxidant complexes. All patients underwent PBM every 6 months. The five-year prevalence of early and intermediate AMD was estimated using data from leading ophthalmological centers in Ukraine (Odesa - 7.1%, Kharkiv - 6.6%) and Moldova (6.3%). AMD progression in the multivariate Cox regression model over five years showed a 3.24-fold reduction in relative risk (95% CI: 2.15-4.79, p=0.000) for patients with early and intermediate AMD who regularly took the recommended nutraceutical (compared to those who irregularly took various vitamin-antioxidant complexes). Patients with early and intermediate AMD are recommended to undergo courses of PBM every six months. Additionally, it is crucial to address cardiovascular issues and consistently use the AREDS2 nutraceutical formula. Adherence to these recommendations can reduce the likelihood of disease progression by at least 3.24 times over the next 5 years.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View on DOI ↗View on PubMed ↗

Reducing the risk of age-related macular degeneration progression - five-year follow-up study in Ukraine and Moldova

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief